Is Moderna a Buy After Its Latest Round of Horrible News?
When it rains, it pours. A few weeks ago Moderna (NASDAQ: MRNA) reported some concerning safety data for its experimental flu vaccine. Last week, the company had more bad news.
On Tuesday, Bloomberg reported that COVID-19 Vaccines Global Access (COVAX) and the African Union declined options to buy more doses of Moderna's Spikevax COVID-19 vaccine. At the end of the week, Moderna revealed that it was recalling thousands of doses of the Spikevax vaccine in Europe.
Moderna's shares fell 9% last week. Is the vaccine stock a buy after this latest round of horrible news?
Source Fool.com
